| Author | Perazzo, Hugo | |
| Author | Castro, Rodolfo | |
| Author | Villela-Nogueira, Cristiane | |
| Author | Torres, Marcos | |
| Author | Silva, Samara Luiza | |
| Author | Cardoso, Sandra W. | |
| Author | Grinsztejn, Beatriz | |
| Author | Veloso, Valdiléa G. | |
| Access date | 2023-12-22T19:39:38Z | |
| Available date | 2023-12-22T19:39:38Z | |
| Document date | 2023 | |
| Citation | PERAZZO, Hugo et al. Acceptability and usability of oral fluid HCV self-testing for hepatitis C diagnosis: A systematic review and meta-analysis. Journal of Viral Hepatitis, p. 838–847, Nov. 2023. | en_US |
| ISSN | 1352-0504 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/61933 | |
| Language | eng | en_US |
| Publisher | Blackwell Scientific Publications | en_US |
| Rights | restricted access | en_US |
| Title | Acceptability and usability of oral fluid HCV self-testing for hepatitis C diagnosis: A systematic review and meta-analysis | en_US |
| Type | Article | en_US |
| DOI | 10.1111/jvh.13876 | |
| Abstract | Data on the acceptability and usability of hepatitis C virus self-testing (HCVST) remain scarce. We estimated the pooled rates of acceptability/feasibility and re-reading/re testing agreement of HCVST using oral fluid tests (PROSPERO-CRD42022349874). We searched online databases for studies that evaluated acceptability, usability and inter-reader/operator variability for HCVST using oral fluid tests. Pooled estimates of feasibility, agreement and post-testing perspectives were analysed. Sensitivity analyses were performed in men who have sex with men (MSM) and people who inject drugs (PWID). Heterogeneity was assessed using the I2 statistics. A total of six studies comprising 870 participants were identified: USA (n= 95 with liver disease), Kenya (n= 150 PWID), Egypt (n= 116 from the general population), Vietnam (n= 104 MSM and n= 105 PWID), China (n= 100 MSM) and Georgia (n= 100 MSM and n= 100 PWID)]. All studies used OraQuick® HCV Rapid Antibody Test. The pooled overall es timates for correct sample collection and for people who performed HCVST without needing assistance in any step (95% confidence interval [CI]) were 87.2% [76.0–95.3] (n= 755; I2= 93.7%) and 62.6% [37.2–84.8] (n= 755; I2= 98.0%), respectively. The pooled estimate of agreement for re-reading was 95.0% [95% CI 91.5–97.6] (n= 831; I2= 74.0%) and for re-testing was 94.4% [90.3–97.5] (n= 726; I2= 77.1%). The pooled estimate of those who would recommend HCVST was 94.4% [84.7–99.6] (n= 625; I2= 93.7%). Pooled estimates (95% CI) of correct sample collection (72.8% [63.3–81.5] vs. 90.8% [85.9–94.8]) and performance of HCVST without needing assistance (44.1% [14.1–76.7] vs. 78.1% [53.4–95.3]) was lower in PWID compared to MSM. In summary, HCV testing with oral fluid HCVST was feasible and well-accepted. Oral fluid HCVST should be considered in key populations for uptake HCV testing. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Sergio Arouca National School of Public Health. Rio de Janeiro, RJ, Brazil / Federal University of the State of Rio de Janeiro. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. School of Medicine. Department of Internal Medicine. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Subject | Feasibility | en_US |
| Subject | HCV testing | en_US |
| Subject | Screening | en_US |
| Subject | Self-testing | en_US |
| Subject | Viral hepatitis | en_US |
| e-ISSN | 1365-2893 | |
| Embargo date | 2030-12-31 | |
